Analysed TURN THERAPEUTICS INC (TTRX:NASDAQ) News Sources
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
01-06-2026
yahoo.com
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
06-07-2026
yahoo.com
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
07-07-2026
yahoo.com
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis
07-07-2026
yahoo.com
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
11-07-2026
marketbeat.com
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
12-08-2026
yahoo.com
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
09-09-2026
yahoo.com
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
21-10-2026
pharmavoice.com
What is the current price of TURN THERAPEUTICS INC (TTRX:NASDAQ)?
The current price of TURN THERAPEUTICS INC (TTRX:NASDAQ) is $10.6.
TURN THERAPEUTICS INC (TTRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TURN THERAPEUTICS INC (TTRX:NASDAQ) since the previous trading day is $0.32.
TURN THERAPEUTICS INC (TTRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TURN THERAPEUTICS INC (TTRX:NASDAQ) since the previous trading day is 3.1128%.
What is the most recent average sentiment score for TURN THERAPEUTICS INC (TTRX:NASDAQ)?
The most recent average sentiment score for TURN THERAPEUTICS INC (TTRX:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for TURN THERAPEUTICS INC (TTRX:NASDAQ)?
The most recent sentiment for TURN THERAPEUTICS INC (TTRX:NASDAQ) is .
SEC-8K** Filing Available For TURN THERAPEUTICS INC (TTRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.